Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
27.18
-0.39 (-1.41%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Tango Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 157.83 | 112.28 | 69.53 | 66.39 | 59.97 | 142.75 |
Short-Term Investments | 222.01 | 230.86 | 188.39 | 270.5 | 306.17 | 342.51 |
Cash & Short-Term Investments | 379.84 | 343.14 | 257.92 | 336.89 | 366.13 | 485.26 |
Cash Growth | 75.26% | 33.04% | -23.44% | -7.99% | -24.55% | 154.97% |
Accounts Receivable | - | - | - | - | 2 | 2 |
Other Current Assets | 12.49 | 10.62 | 8.43 | 9.65 | 7.14 | 5.08 |
Total Current Assets | 392.33 | 353.76 | 266.34 | 346.54 | 375.27 | 492.34 |
Net Property, Plant & Equipment | 41.03 | 42.49 | 47.58 | 53.42 | 57.77 | 6.09 |
Other Long-Term Assets | 2.43 | 2.44 | 2.57 | 2.61 | 3.43 | 1.73 |
Total Assets | 435.79 | 398.69 | 316.49 | 402.57 | 436.47 | 500.16 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.43 | 1.18 | 1.6 | 2.79 | 4.45 | 3.23 |
Accrued Expenses | 9.07 | 17.76 | 16.5 | 15.4 | 17.5 | 9.89 |
Current Portion of Leases | 2.83 | 2.74 | 2.45 | 2.08 | 1.77 | 1.5 |
Unearned Revenue | - | - | 17.62 | 25.67 | 31.79 | 26.02 |
Other Current Liabilities | - | - | - | - | 0.04 | 0.05 |
Total Current Liabilities | 14.33 | 21.68 | 38.17 | 45.94 | 55.55 | 40.69 |
Long-Term Leases | 29.96 | 30.83 | 34.04 | 36.84 | 39.36 | - |
Other Long-Term Liabilities | - | - | 44.77 | 66.68 | 92.09 | 114.72 |
Total Long-Term Liabilities | 29.96 | 30.83 | 78.81 | 103.52 | 131.45 | 114.72 |
Total Liabilities | 44.29 | 52.51 | 116.98 | 149.46 | 186.99 | 155.41 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.14 | 0.14 | 0.11 | 0 | 0.09 | 0.09 |
Additional Paid-in Capital | 1,040 | 948.97 | 700.63 | 624.08 | 522.61 | 506.76 |
Accumulated Other Comprehensive Income | -0.12 | 0.22 | 0.34 | 0.19 | -3.71 | -0.77 |
Retained Earnings | -648.67 | -603.15 | -501.56 | -371.26 | -269.51 | -161.34 |
Total Common Shareholders' Equity | 391.51 | 346.18 | 199.52 | 253.11 | 249.48 | 344.75 |
Shareholders' Equity | 391.51 | 346.18 | 199.52 | 253.01 | 249.48 | 344.75 |
Total Liabilities & Equity | 435.79 | 398.69 | 316.49 | 402.57 | 436.47 | 500.16 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 32.79 | 33.57 | 36.49 | 38.92 | 41.13 | 1.5 |
Net Cash (Debt) | 347.05 | 309.57 | 221.42 | 297.97 | 325 | 483.75 |
Net Cash Growth | 93.04% | 39.81% | -25.69% | -8.32% | -32.82% | 165.16% |
Net Cash Per Share | 2.76 | 2.67 | 2.03 | 3.15 | 3.70 | 7.79 |
Book Value | 391.51 | 346.18 | 199.52 | 253.11 | 249.48 | 344.75 |
Book Value Per Share | 3.11 | 2.98 | 1.83 | 2.68 | 2.84 | 5.55 |
Tangible Book Value | 391.51 | 346.18 | 199.52 | 253.11 | 249.48 | 344.75 |
Tangible Book Value Per Share | 3.11 | 2.98 | 1.83 | 2.68 | 2.84 | 5.55 |